home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

16.12 +0.66 (+4.27%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year? ↗

September 19, 2024

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study.

Via The Motley Fool

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous. ↗

September 18, 2024

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

Via The Motley Fool

How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery ↗

September 17, 2024

BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.

Via Investor's Business Daily

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗

September 17, 2024

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...

Via Benzinga

Here's Why Everyone's Talking About Summit Therapeutics ↗

September 17, 2024

Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.

Via The Motley Fool

Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today ↗

September 13, 2024

Via Benzinga

Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment ↗

September 11, 2024

Via Benzinga

Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday ↗

September 16, 2024

Via Benzinga

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

September 16, 2024

From Summit Therapeutics Inc.

Via Business Wire

Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio? ↗

September 15, 2024

These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings.

Via Benzinga

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? ↗

September 14, 2024

A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.

Via The Motley Fool

Why Summit Therapeutics Skyrocketed 123% This Week ↗

September 13, 2024

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers.

Via The Motley Fool

Why Summit Therapeutics Stock Is Soaring Again Today ↗

September 12, 2024

This high-flying biotech stock is moving even higher -- and for good reason.

Via The Motley Fool

Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday ↗

September 12, 2024

Via Benzinga

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale ↗

September 12, 2024

The company is adding onto its success outperforming Merck's top drug in lung cancer patients.

Via Investor's Business Daily

Summit Therapeutics Surges on Trial Results: Time to Buy?

September 12, 2024

Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab.

Via MarketBeat

Why Summit Therapeutics (SMMT) Stock Is Rising Today ↗

September 12, 2024

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net proceeds.

Via Benzinga

Summit Therapeutics Raises $235 Million

September 12, 2024

From Summit Therapeutics Inc.

Via Business Wire

Is Summit Therapeutics a Buy Now? ↗

September 10, 2024

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.

Via The Motley Fool

Why Summit Therapeutics Rocketed Over 60% Today ↗

September 09, 2024

The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market.

Via The Motley Fool

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday ↗

September 09, 2024

Via Benzinga

Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda ↗

September 09, 2024

Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%.

Via Investor's Business Daily

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half ↗

September 09, 2024

Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,...

Via Benzinga

Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

September 09, 2024

Via Benzinga

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

September 08, 2024

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 06, 2024

From Summit Therapeutics Inc.

Via Business Wire

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

August 12, 2024

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 09, 2024

From Summit Therapeutics Inc.

Via Business Wire

SMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024 ↗

August 06, 2024

SMMT stock results show that Summit Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com